Oxyle's Water Catalyst After the EIC Accelerator: Replaced by UV

The European Innovation Council paid for a catalyst. Oxyle kept the mission and dropped the catalyst. The Zurich start-up, founded in 2020 by two ETH Zurich researchers, was selected in the 7 October 2020 cut-off of the EIC Accelerator pilot, according to the European Commission's list of selected companies, which names Oxyle as the only beneficiary of the WATERACT project, with grant-only funding. CORDIS puts the EU contribution at €2,042,000 towards a total cost of €2,917,166.25, for a project that ran from 1 May 2021 to 30 April 2023. The promise was to bring small reactors that destroy "over 90%" of toxic micropollutants in wastewater "to market in 2023".

That product launch was never announced. In July 2025 Oxyle said it had made "the strategic decision to retire their early-stage technology, the piezocatalyst", and relaunched itself around three technologies for PFAS, the so-called forever chemicals, led by a UV-light process called OxLight, according to the company's announcement. In August 2025 the trade publication Aquatech described the same turn, from the company's early groundwater work to short-chain PFAS in industrial water. The company is active, funded and growing. By the definition used here it has pivoted: its lead product is no longer the technology the EIC funded.

What Oxyle Does Today

Oxyle now sells modular PFAS treatment built from three in-house technologies: OxFoam, which separates and concentrates PFAS by foam fractionation; OxLight, a "photochemical reduction" step that destroys them, including short and ultra-short chains; and OxSignal, a real-time monitoring platform, according to its July 2025 launch. OxLight combines UV light with "proprietary mediator chemicals", according to the company's profile on the UBS Global Visionaries programme, which says Oxyle has treated over 3 million litres of contaminated water. Swiss public broadcaster SRF described the same sequence in November 2025: PFAS are separated and concentrated first, then broken apart with UV light and chemicals.

The customers are industrial. Aquatech names textiles, pharmaceuticals and pesticides as target sectors, and reported a six-month full-scale pilot with a Swiss remediation customer in 2024 plus plans for at least two pilots in 2026, one in Switzerland and one in the Benelux. In July 2026 the Belgian trade site Aquarama reported an on-site pilot with an unnamed industrial client in which Oxyle destroyed more than 99.9% of a C3 PFAS. No customer has been named publicly, and the performance figures come from the company.

The Technology the EIC Funded

WATERACT rested on what CORDIS calls a "novel catalytic material" that "continuously" generates "high doses of oxidizing radicals" to break down micropollutants such as antibiotics, pesticides, hormones and pharmaceuticals, which conventional treatment plants remove only in part. The catalyst needed an energy input: the project's final report describes work on "new actuation mechanisms", and TechCrunch reported in 2022 that "water movements" such as bubbling or vibration activated Oxyle's nanoporous catalyst. The idea came from Mushtaq's doctoral work at ETH Zurich. An earlier ERC Proof of Concept grant at ETH, SMART (€150,000, October 2019 to July 2021), funded catalytic membranes that generate surface charges under magnetic fields, light and mechanical vibration, and startupticker.ch listed an ERC Proof of Concept among Oxyle's early funders in 2021.

Against activated carbon and membranes, which move pollutants into spent carbon or concentrate rather than destroying them, the pitch was destruction without secondary waste, TechCrunch reported. The project report also claimed it avoided "harmful chemicals". No independent test of the catalyst's performance at scale has been published.

What WATERACT Promised, and What CORDIS Shows

The CORDIS objective is unusually concrete. Oxyle planned to have "70 operational small-scale reactors providing efficient treatment to eight customers in 2023", and by 2026 "5620 operational reactors in all three cleaning sizes" serving 762 clients and generating €139 million in revenue, with income from licence fees and recurring catalyst sales. The project's planned deliverables included a "Certified Reactor SS product" and on-site demonstrations of the small-scale reactor, according to the CORDIS results page.

The final periodic report, covering May 2022 to April 2023, lists catalyst work: production cost cut by 70%, a "100x higher throughput" in catalyst production, standard operating procedures, inline water-quality sensors and market research. On reactors it says the team was "currently constructing demo units and looking for right manufacturing partner". That is the state of the hardware at the end of the project, the year the reactors were meant to be on the market.

1. Scale up catalyst productionDelivered70% lower cost and 100x throughput, per the final report.
2. On-site customer pilotsDeliveredPaid pilots by 2022 (TechCrunch); over 20 customer projects by 2025.
3. Small-scale reactors on the market in 2023Not achievedDemo units still under construction in April 2023; no launch announced.
4. Certified small-scale reactor productNot achievedNo certification announced by the company or a third party.
5. 70 reactors with 8 customers in 2023Not achievedNo reactor count published; first full-scale system came in November 2024.
6. 5,620 reactors and €139M revenue in 2026Not achievedCatalyst retired in July 2025; no revenue figure is public.

The project closed on time on 30 April 2023, and the EC signed the grant agreement on 28 April 2021, more than six months after the cut-off. Fairly judged, WATERACT industrialised the catalyst and supported paid pilots, but the reactor product it was meant to launch did not appear, and the company has since abandoned the catalyst itself.

What Oxyle Has Achieved Since the Award

The money arrived after the project. In December 2022 Oxyle announced a $3 million pre-seed round led by Wingman Ventures with SOSV, Better Ventures and another.vc, bringing its total raised, grants included, to $7.4 million, with 17 staff, according to TechCrunch. The commercial register shows a capital increase with new preferred shares in November 2022, according to Moneyhouse.

On 30 January 2025 the company announced a $16 million seed round led by 360 Capital with Axeleo Capital, Founderful and SOSV, bringing total funding to $26 million including non-dilutive grants and awards, according to Water Online and startupticker.ch. Aquatech gave the round as €14.6 million. The same release said Oxyle's first full-scale system had gone into operation in Switzerland in November 2024, treating 10 cubic metres of contaminated groundwater per hour at under 1 kWh per cubic metre, and that the team numbered 26. Startupticker described that system as combining foam fractionation, catalytic destruction and machine-learning monitoring, which suggests the funded catalyst reached one full-scale installation before it was retired.

The Swiss commercial register records the seed round. On 23 January 2025 the share capital rose from CHF 128,869.60 to CHF 188,676.60, partly by converting claims of CHF 2,999,948.44 into seed preferred shares, and the company moved its seat to Schlieren. Bradley James Nelson left the board and Thomas Nivard, the 360 Capital partner quoted in the funding release, joined it. The register shows no insolvency or liquidation entry. Swiss private companies do not file public accounts, so revenue, losses and cash could not be verified.

Recognition has followed the PFAS turn. The UBS profile lists a Green Business Award (2026), a World Economic Forum UpLink Top Innovator title (2025) and a Swiss Technology Award (2024), and the company's leadership page now names a separate CTO, CCO, COO and general counsel alongside the two founders, according to Oxyle. Its own timeline describes 2021 to 2023 as the move "from lab to prototype" and 2025 as the year of its "first OxLight pilots".

Why Europe Should Care

Both of Oxyle's markets are being created by EU law. The revised Urban Wastewater Treatment Directive, in force since 1 January 2025, requires quaternary treatment to remove micropollutants and makes the polluting sectors pay for it through extended producer responsibility. Directive (EU) 2024/3019 says all plants of 150,000 population equivalent and above should provide it, phased in until 2045, with pharmaceuticals and cosmetics named as the producers concerned. That is exactly the market WATERACT targeted. The recast Drinking Water Directive covers PFAS among its "emerging contaminants", the market Oxyle now serves.

The physics sets limits. ETH Zurich environmental chemist Martin Scheringer told SRF that PFAS already in the environment are "like the milk in the coffee" and estimated that Oxyle's method would need about a million years to clean Lake Geneva. Treating concentrated industrial streams at the source, where Oxyle now focuses, is the realistic use.

The Verdict

Oxyle has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.